We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
-23.11%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$124M
AUM Growth
-$37.4M
Cap. Flow
+$4.08M
Cap. Flow %
3.3%
Top 10 Hldgs %
86.46%
Holding
31
New
6
Increased
8
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$18.5M
2
ELEV
Elevation Oncology
ELEV
+$3.36M
3
LVTX
LAVA Therapeutics
LVTX
+$2.18M
4
KZR
Kezar Life Sciences
KZR
+$2.18M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.14M

Top Sells

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$26.1M
2
WHWK
Whitehawk Therapeutics
WHWK
+$548K
3
PVLA
Palvella Therapeutics
PVLA
+$506K
4
ACHL
Achilles Therapeutics
ACHL
+$384K
5
LENZ
LENZ Therapeutics
LENZ
+$268K

Sector Composition

Rank Sector Weight
1 Healthcare 98.84%
2 Technology 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
26
DELISTED
HilleVax
HLVX
$30.1K 0.02%
20,760
– –
SGOV icon
27
iShares 0-3 Month Treasury Bond ETF
SGOV
$99.4B
– –
-260,000
Closed -$26.1M
LENZ
28
LENZ Therapeutics
LENZ
$179M
– –
-9,271
Closed -$268K
PVLA
29
Palvella Therapeutics
PVLA
$2.05B
– –
-42,130
Closed -$506K
KLRS
30
Kalaris Therapeutics
KLRS
$80.9M
– –
-8,011
Closed -$77.4K
ACHL
31
DELISTED
Achilles Therapeutics
ACHL
$0 ﹤0.01%
3,804,921
-295,081
-7% -$384K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return
SPM
Summit Portfolio Management Las Vegas, Nevada $155M AUM
MCA
McGuire Capital Advisors Bethany, Oklahoma $156M AUM

BML Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, BML Capital Management held 31 positions worth $124M, down 23% from $161M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

BML Capital Management deployed $4.08M of net new capital in Q1 2025, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Third Harmonic Bio: 3,824,417 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 83% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Whitehawk Therapeutics, an estimated $548K trimmed.

  • BML Capital Management's largest Q1 2025 buy was Third Harmonic Bio: 3,824,417 shares worth $13.3M.
  • BML Capital Management added most to Kezar Life Sciences in Q1 2025, an estimated $2.18M increase.
  • BML Capital Management's biggest Q1 2025 reduction was Whitehawk Therapeutics, cutting an estimated $548K.
  • BML Capital Management fully exited iShares 0-3 Month Treasury Bond ETF in Q1 2025, selling an estimated $26.1M.
  • BML Capital Management's ten largest holdings make up 86% of its $124M portfolio in Q1 2025.
  • BML Capital Management opened 6 new positions and closed 4 in Q1 2025.
  • BML Capital Management's portfolio value fell 23% quarter-over-quarter to $124M.

Based on BML Capital Management's 13F filing for Q1 2025, filed 7 May 2025.